KRAS and colorectal cancer: For example, colorectal cancer (CRC) patients with coexisting KRAS and PIK3CA (phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha) mutations, do not respond to therapy [89].